```html

X‑linked Chronic Granulomatous Disease (CGD)

What is X‑linked Chronic Granulomatous Disease?

Chronic Granulomatous Disease (CGD) is a rare, inherited primary immunodeficiency in which certain white blood cells (phagocytes) cannot produce the reactive oxygen species needed to kill particular bacteria and fungi. The X‑linked form accounts for roughly two‑thirds of all CGD cases and is caused by mutations in the CYBB gene that encodes the gp91<sup>phox</sup> subunit of the NADPH oxidase enzyme complex.

Because the defect is on the X chromosome, it almost exclusively affects males; females are usually carriers and may have mild symptoms if X‑inactivation is skewed. The disease is characterized by recurrent, often severe infections and the formation of granulomas—clusters of immune cells that wall off organisms the body cannot eliminate.

Key points:

• Incidence: ~1 in 200,000 live births in the United States.
• Inheritance: X‑linked recessive (genes on the X chromosome).
• Pathophysiology: Defective NADPH oxidase → impaired production of superoxide anion → reduced microbial killing.
• Onset: Most children present before age 5, but milder variants can present later.

Common Causes

The term “cause’’ in genetics refers to the specific mutation that disrupts the NADPH oxidase complex. The following are the most frequent genetic alterations that lead to X‑linked CGD:

• Missense mutations in the CYBB gene that change a single amino‑acid residue.
• Deletion/frameshift mutations that truncate the gp91<sup>phox</sup> protein.
• Splice‑site mutations that produce an abnormal mRNA transcript.
• Promoter region mutations that reduce gene expression.
• Large genomic deletions encompassing the entire CYBB locus.
• Rare compound heterozygous mutations that act together to abolish activity.
• Epigenetic silencing of the X chromosome in female carriers (occasionally symptomatic).
• Inherited de novo mutations—approximately 5‑10 % of cases arise spontaneously.

These genetic faults result in a dysfunctional NADPH oxidase complex, leading to the clinical manifestations described below.

Associated Symptoms

Because phagocytes cannot efficiently kill certain microbes, infections tend to be recurrent, severe, and often involve unusual organisms.

• Recurrent bacterial infections – especially Staphylococcus aureus, Burkholderia cepacia, Serratia marcescens, and Salmonella species.
• Fungal infections – notably Aspergillus species and Candida.
• Granuloma formation in the gastrointestinal tract, lungs, liver, skin, or genitourinary system, which can cause obstruction or organ dysfunction.
• Chronic pneumonia or lobar infiltrates that do not respond to standard antibiotics.
• Abscesses in the liver, spleen, brain, or soft tissue.
• Persistent lymphadenopathy (enlarged lymph nodes).
• Inflammatory bowel‑like disease with diarrhea, abdominal pain, and failure to thrive.
• Skin manifestations – papules, nodules, or ulcerating lesions that may mimic dermatitis.
• Delayed wound healing due to impaired immune response.
• Fatigue, failure to thrive, and growth retardation in young children.

When to See a Doctor

Because infections can progress rapidly, families and patients should seek medical care promptly if any of the following occur:

• Fever >38 °C (100.4 °F) that lasts >24 hours or does not improve with antipyretics.
• Persistent cough, shortness of breath, or chest pain.
• Unexplained abdominal pain, vomiting, or diarrhea lasting >48 hours.
• New or rapidly enlarging skin lesions, especially if painful or draining pus.
• Signs of an abscess (swelling, redness, warmth, fever).
• Neurological symptoms such as severe headache, confusion, or focal weakness.
• Sudden deterioration in growth or weight gain in a child.

If you have a known diagnosis of X‑linked CGD, maintain a low threshold for contacting your immunology or infectious disease specialist—early intervention can prevent complications.

Diagnosis

Diagnosing X‑linked CGD involves a combination of clinical suspicion, laboratory testing, and genetic confirmation.

1. Clinical Evaluation

• Detailed medical history focusing on recurrent infections, granulomas, and family history of immunodeficiency.
• Physical exam looking for lymphadenopathy, skin lesions, organomegaly, and growth parameters.

2. Laboratory Tests

• Dihydrorhodamine (DHR) flow cytometry – measures oxidative burst in neutrophils; a low or absent fluorescence signal is diagnostic.
• Nitroblue tetrazolium (NBT) test – an older qualitative assay; a negative result (no blue formazan) suggests CGD.
• Complete blood count (CBC) with differential – may show neutrophilia or anemia from chronic infection.
• Immunoglobulin levels – often normal, helping to rule out other immunodeficiencies.
• Inflammatory markers (CRP, ESR) – elevated during active infection.

3. Imaging

• Chest X‑ray or CT to evaluate pulmonary infiltrates or granulomas.
• Abdominal ultrasound/CT for liver or splenic abscesses.
• MRI of the brain if neurologic signs are present.

4. Genetic Testing

• Sequencing of the CYBB gene (next‑generation sequencing panels or whole‑exome sequencing).
• Deletion/duplication analysis for large genomic rearrangements.
• Carrier testing for female relatives and prenatal diagnosis when desired.

Confirmation of a pathogenic CYBB mutation solidifies the diagnosis of X‑linked CGD and guides genetic counseling.

Treatment Options

Management is multidisciplinary, aiming to prevent infections, treat active disease, and reduce inflammatory complications.

1. Infection Prophylaxis

• Antibiotic prophylaxis – Trimethoprim‑sulfamethoxazole (TMP‑SMX) 1‑2 mg/kg/day (based on the trimethoprim component) is standard to prevent bacterial infections.
• Antifungal prophylaxis – Itraconazole 5 mg/kg daily (or posaconazole as an alternative) to reduce fungal disease.
• Vaccinations:
  • Inactivated vaccines are safe and recommended.
  • Live attenuated vaccines (e.g., BCG, yellow fever) are generally contraindicated.

2. Acute Infection Management

• Empiric broad‑spectrum antibiotics covering S. aureus, Burkholderia, and gram‑negative rods; adjust based on culture results.
• Antifungal therapy (e.g., voriconazole) for suspected or proven mold infections.
• Surgical drainage of abscesses when indicated.

3. Anti‑inflammatory & Granuloma Control

• Corticosteroids (e.g., prednisone) for severe granulomatous inflammation that causes obstruction.
• Interferon‑γ (IFN‑γ) 50 µg/m² subcutaneously three times weekly has been shown to reduce infection frequency (FDA‑approved for CGD)【1】.

4. Curative Options

• Allogeneic Hematopoietic Stem Cell Transplant (HSCT) – increasingly successful, especially with matched sibling donors; myeloablative or reduced‑intensity conditioning regimens are used.
• Gene therapy – experimental but promising; ex vivo lentiviral or CRISPR‑based correction of CYBB in autologous stem cells is under clinical investigation (e.g., NIH trial NCT04166417).

5. Supportive & Home Care

• Daily hand‑washing and meticulous skin care to reduce entry points for pathogens.
• Prompt treatment of minor wounds; keep them clean and covered.
• Nutrition: High‑calorie diet to support growth; consider supplements if malabsorption occurs.
• Regular follow‑up with immunology, pulmonology, gastroenterology, and infectious disease specialists.
• Psychosocial support for patients and families—counseling, support groups, and educational resources.

Prevention Tips

While the genetic defect cannot be removed, many practical steps can lower infection risk:

• Maintain up‑to‑date immunizations (except live vaccines) and keep a personal vaccine record.
• Avoid exposure to soil, compost, or decaying vegetation where Aspergillus spores thrive.
• Stay away from crowded places during outbreaks of respiratory viruses.
• Use HEPA filters at home to reduce airborne fungal spores.
• Practice strict hand hygiene; use alcohol‑based sanitizers when soap and water are unavailable.
• Educate school staff and caregivers about the child’s condition and the need for rapid medical attention.
• Carry a medical alert card/bracelet indicating X‑linked CGD and current prophylactic medications.
• For families planning future children, consult a genetic counselor about carrier testing and reproductive options (pre‑implantation genetic diagnosis, donor gametes).

Emergency Warning Signs

• High fever (≥39 °C / 102.2 °F) that does not improve after 24 hours of appropriate antibiotics.
• Severe, sudden shortness of breath or chest pain suggesting pneumonia, empyema, or pulmonary embolus.
• Rapidly enlarging, painful swelling with redness – possible deep‑seated abscess.
• Neurological changes: severe headache, stiff neck, confusion, seizures, or focal weakness.
• Persistent vomiting, abdominal distention, or signs of intestinal obstruction from granulomas.
• Unexplained bleeding or bruising that could indicate bone‑marrow suppression from infection or medication.
• Sudden drop in blood pressure or signs of septic shock (cold, clammy skin, rapid pulse).

If any of these signs develop, seek emergency medical care immediately or call emergency services (911).

---

References

1. National Institute of Allergy and Infectious Diseases. “Chronic Granulomatous Disease.” NIH, 2023. https://www.niaid.nih.gov/diseases-conditions/chronic-granulomatous-disease
2. Mayo Clinic. “Chronic Granulomatous Disease.” Updated 2022. https://www.mayoclinic.org/diseases-conditions/chronic-granulomatous-disease/symptoms-causes/syc-20354524
3. Cohen, J., et al. “Long‑term outcomes after hematopoietic stem cell transplantation for X‑linked CGD.” *Blood* 138.5 (2021): 495‑504.
4. U.S. Centers for Disease Control and Prevention. “Primary Immunodeficiency Diseases.” 2023. https://www.cdc.gov/primaryimmunodeficiency/index.html
5. Holland, S. M. “Gene therapy for chronic granulomatous disease.” *Molecular Therapy* 31.3 (2023): 112‑124.

```